Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Control or miR-28-transduced MD-901 tumors grown in NSG mice and treated with ibrutinib

ABSTRACT: Control or miR-28-transduced MD-901 tumors grown in NSG mice and treated with ibrutinib

PROVIDER: PRJNA955824 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24178831.fastq.gz	Fastqsanger.gz
	SRR24178832.fastq.gz	Fastqsanger.gz
	SRR24178833.fastq.gz	Fastqsanger.gz
	SRR24178834.fastq.gz	Fastqsanger.gz
	SRR24178835.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Control or miR-28-transduced MD-901 tumors grown in NSG mice and treated with ibrutinib

Project description:Diffuse large B cell lymphoma (DLBCL) is the most common aggressive B cell lymphoma and accounts for nearly 40% of cases of B cell non-Hodgkin lymphoma. DLBCL is generally treated with R-CHOP chemotherapy, but many patients do not respond or relapse after treatment. Here, we analyzed the therapeutic potential of the tumor suppressor microRNA-28 (miR-28) for DLBCL, alone and in combination with the Bruton’s tyrosine kinase inhibitor ibrutinib. Combination therapy with miR-28 plus ibrutinib potentiated the anti-tumor effects of monotherapy with either agent by inducing a specific transcriptional cell-cycle arrest program that impairs DNA replication. The molecular actions of miR-28 and ibrutinib synergistically impair DNA replication by simultaneous inhibition of origin activation and fork progression. Moreover, we found that downregulation of the miR-28-plus-ibrutinib gene signature correlates with better survival of ABC-DLBCL patients. These results provide evidence for the effectiveness of a new miRNA-based ibrutinib combination therapy for DLBCL and unveil the miR-28-plus-ibrutinib gene signature as a new predictor of outcome in ABC-DLBCL patients.

2023-09-21 | GSE229784 | GEO

MD-901 cells treated with ibrutinib and/or miR-28 in vitro

Project description:MD-901 cells treated with ibrutinib and/or miR-28 in vitro

| PRJNA955823 | ENA

MD-901 cells treated with ibrutinib and/or miR-28 in vitro

2023-09-21 | GSE229785 | GEO

Thermobifida fusca strain:UPMC 901 | isolate:UPMC 901

Project description:Thermobifida fusca strain:UPMC 901 | isolate:UPMC 901 Genome sequencing

| PRJNA669597 | ENA

Saccharina japonica cultivar 901

Project description:Saccharina japonica cultivar 901 Genome sequencing

| PRJNA919482 | ENA

Transcription profiling of Smarce1- MD (R42A) and Smarce1- MD mouse embryonic body

Project description:To evaluate the differential potential affected by SMARCE1 -MD/MD(R42A) , we performed RNA-sequencing (RNA-seq) of Smarce1-MD and control Smarce1-MD (R42A) embrynoic body.

2023-03-19 | GSE216662 | GEO

Treg transcriptomic profile in NSG, NSG+Thymus humanized mice and healthy donors (HD)

Project description:RNA sequencing was performed on RNA extracted from human Treg cells from NSG, NSG+Thymus humanized mice and healthy donors

2021-11-02 | GSE186881 | GEO

EGR1-mediated ibrutinib resistance

Project description:We established two representative ABC DLBCL cell lines (TMD8 and OCI-Ly10) with ibrutinib resistance by gradually increasing the concentration of ibrutinib during passage in culture. RNA-seq analysis demonstrated that the BCR pathway gene signature is enriched in resistant cell lines when compared to parental cells. The most upregulated gene is EGR1, a transcription factor that activates multiple oncogenic pathways including MYC and E2F. Elevated EGR1 expression is also observed in ibrutinib-resistant primary mantle cell lymphoma cells when treated with ibrutinib. Using multiple metabolic and genetic approaches, we discovered that overexpression of EGR1 causes metabolic reprogramming to oxidative phosphorylation (OXPHOS) and ibrutinib resistance. Mechanistically, EGR1 mediates metabolic reprogramming through transcriptional activation of PDP1, a phosphatase that dephosphorylates and activates the E1 component of the large pyruvate dehydrogenase complex. Therefore, EGR1-mediated PDP1 activation accelerates intracellular ATP production via the mitochondrial tricarboxylic acid (TCA) cycle, leading to sufficient energy to enhance the proliferation and survival of ibrutinib-resistant lymphoma cells. Finally, we demonstrate that targeting OXPHOS with IM156, a newly developed OXPHOS inhibitor, inhibits the growth of ibrutinib-resistant lymphoma cells both in vitro and in patient-derived xenograft mouse models.

2023-12-06 | GSE223150 | GEO

Ibrutinib induces a global chromatin reorganisation in chronic lymphocytic leukaemia

Project description:Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in developed countries. Ibrutinib (PCI-32765), a specific and irreversible inhibitor of Bruton's Tyrosine Kinase (BTK) represents a major step forward in the treatment of CLL. We have undertaken a detailed analysis of the changes happening to the chromatin structure in CLL cells from patients continuously receiving oral doses of ibrutinib. ChIP-seq has been performed for H3K4me3, H3K27ac, H3K27me3 and EZH2 up to 56 days following the beginning of the treatment. We observed that Ibrutinib-dependent lymphocytosis correlates with a global and transient recruitment of EZH2 to active cis-regulatory elements and increased H3K27me3.

2019-06-01 | E-MTAB-6410 | biostudies-arrayexpress

Populus trichocarpa strain:BESC-901

Project description:Populus trichocarpa strain:BESC-901 Genome sequencing

| PRJNA256593 | ENA